Want to see NBP full AI Analyst Report?
NBP Stock Chart & Stats
$2.70
--
Market closed
$2.70
--
Day’s Range― - ―
52-Week Range$1.46 - $6.79
Previous CloseN/A
VolumeN/A
Average Volume (3M)679.12K
Market Cap
$246.92M
Enterprise Value$1.19B
Total Cash (Recent Filing)$30.14M
Total Debt (Recent Filing)$438.46K
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Sep 01, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding115,381,690
10 Day Avg. Volume531,112
30 Day Avg. Volume679,123
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-8.04
Enterprise Value/Market Cap4.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-37.83
Forecast
1Y Price Target
$9.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthConsistently low leverage and a relatively strong balance sheet materially reduce near-term solvency risk. For a clinical-stage biotech burning cash, low debt preserves optionality to fund trials, pursue partnerships or raise equity without immediate creditor pressure, stabilizing execution.
Regulatory Progress For Lead AssetFast Track designation for givastomig creates structural regulatory benefits: closer FDA interaction, rolling review eligibility and accelerated pathways. This shortens development timelines if Phase 3 succeeds and materially improves the program’s odds of reaching registration and commercialization.
Strengthened Executive And Commercial BenchAdding an experienced biopharma CEO and earlier hiring of a seasoned President/CCO improves strategic and commercial capabilities. Durable benefit: stronger leadership increases likelihood of disciplined registrational planning, partner engagement and effective launch planning if clinical programs succeed.
Bears Say
Sustained Operating LossesMulti-year operating losses since 2021 indicate structural unprofitability versus a profitable 2020. Persistent negative EBIT/EBITDA erodes equity and limits internal funding capacity, forcing reliance on external capital and increasing execution risk over the medium term.
Chronic Negative Cash GenerationA multi-year negative OCF and FCF trend signals ongoing cash burn; while 2025 shows some improvement, free cash flow has been volatile. Structural weak cash generation constrains reinvestment in trials, heightens fundraising frequency and risks dilution or program delays if markets tighten.
Contracting Equity And Negative ROESharply shrinking assets and equity alongside persistently negative ROE evidences value erosion from losses. This reduces financial flexibility, weakens balance-sheet resilience over time, and can make future capital raises more dilutive or costly, hindering long-term strategic options.
NovaBridge Biosciences News
NBP FAQ
What was Novabridge Biosciences’s price range in the past 12 months?
Novabridge Biosciences lowest stock price was $1.46 and its highest was $6.79 in the past 12 months.
What is Novabridge Biosciences’s market cap?
Novabridge Biosciences’s market cap is $246.92M.
When is Novabridge Biosciences’s upcoming earnings report date?
Novabridge Biosciences’s upcoming earnings report date is Sep 01, 2026 which is in 60 days.
How were Novabridge Biosciences’s earnings last quarter?
Currently, no data Available
Is Novabridge Biosciences overvalued?
According to Wall Street analysts Novabridge Biosciences’s price is currently Undervalued.
Does Novabridge Biosciences pay dividends?
Novabridge Biosciences does not currently pay dividends.
What is Novabridge Biosciences’s EPS estimate?
Novabridge Biosciences’s EPS estimate is -0.12.
How many shares outstanding does Novabridge Biosciences have?
Novabridge Biosciences has 115,381,690 shares outstanding.
What happened to Novabridge Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Novabridge Biosciences?
Currently, no hedge funds are holding shares in NBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovaBridge Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (233.33% Upside)
$9.00 (233.33% Upside)
Blogger Sentiment
Bullish
NBP Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 350.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $515.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 5.3%
Last 30 Days ▲ 5.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Company Description
Novabridge Biosciences
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
NBP Stock 12 Month Forecast
Average Price Target
$9.00
▲(233.33% Upside)
Ownership Overview
0.62% Insiders
0.07% Mutual Funds
13.39% Other Institutional Investors
84.79% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---